immunotherapy

Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference

NEEDHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage…

12 months ago

PDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023

PRINCETON, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing…

12 months ago

Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., Aug. 01, 2023 (GLOBE…

12 months ago

Solve GNE and Gradalis Sign Agreement to Develop a Novel Gene Therapy Targeting HIBM

LOS ANGELES, July 31, 2023 (GLOBE NEWSWIRE) -- Solve GNE announced today that it has entered into a sponsored research…

12 months ago

Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market

WALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology…

12 months ago

Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

Nes-Ziona, Israel, July 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

12 months ago

BioNTech Completes Acquisition of InstaDeep

Acquisition aims to strengthen BioNTech’s pioneering position in the field of AI-powered drug discovery, design and developmentInstaDeep to operate as…

12 months ago

Immutep Quarterly Activities Report Q4 FY23

Media Release Late-stage & registrational trial progress: TACTI-004 Phase III - Positive feedback received from US FDA for planned registrational…

12 months ago

Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023

Media Release Mini Oral presentation will include data from TACTI-002 Phase II trial evaluating chemotherapy-free IO combination of efti plus…

12 months ago

First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Media Release SYDNEY, AUSTRALIA, July 28, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),…

12 months ago